GlaxoSmithKline, criticized in the past for keeping important information about its medicines to itself, is to lift the lid on more of its drug secrets. Three months after GSK was fined $3 billion for fraud in the United States, where prosecutors accused it of concealing safety issues, chief executive Andrew Witty said on Thursday detailed data from its clinical trials would be made available to other researchers. That would include anonymised patient-level results that sit behind clinical trials of approved and failed drugs. Britain's biggest drugmaker will set up an independent panel of experts to review requests submitted by researchers, which will then be vetted for scientific merit, a company spokesman said. The new system will start at the beginning of next year.